Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 0.55 |
| ▸ | SYK | P43405 | 2/20 | 0.55 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.55 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FES | P07332 | 1/20 | 0.43 |
| ▸ | FER | P16591 | 1/20 | 0.43 |
| ▸ | FRK | P42685 | 1/20 | 0.43 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.43 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 3/20 | 0.40 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355321 | 0.85 | TYK2 (0.76) | TYK2SYKIRAK4BRSK1PIK3CA | |
| SCHEMBL3110596 | 0.85 | TYK2 (0.75) | TYK2SYKIRAK4BRSK1PIK3CA | |
| SCHEMBL14085812 | 0.82 | TYK2 (0.49) | TYK2SYKIRAK4BRSK1PIK3CA | |
| SCHEMBL3354609 | 0.81 | KDM4E (0.45) | TYK2SYKIRAK4BRSK1PIK3CA | |
| SCHEMBL3111849 | 0.78 | SYK (0.45) | TYK2SYKIRAK4BRSK1PIK3CA | |
| SCHEMBL14620536 | 0.76 | TYK2 (0.43) | TYK2SYKIRAK4BRSK1PIK3CA | |
| SCHEMBL3360342 | 0.76 | TYK2 (0.43) | TYK2SYKIRAK4BRSK1PIK3CA | |
| SCHEMBL1617491 | 0.73 | PIKFYVE (0.80) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL3329639 | 0.73 | MTOR (0.41) | TYK2SYKIRAK4BRSK1PIK3CA | |
| SCHEMBL14530471 | 0.73 | TYK2 (0.64) | TYK2SYKIRAK4BRSK1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7410990-B2 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410990-B2 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410990-B2 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20070027151-A1 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027151-A1 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027151-A1 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | US | disclosed |
| US-7122665-B2 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1556140-A4 | NOVEL COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1626725-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | Synta Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1556140-A2 | NOVEL COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005000404-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040198725-A1 | A bi-heterocyclic compound e.g 3-methoxyphenyl)-{6-Morpholin-4-yl-2-[2-(pyridin-2-yloxy)-ethoxy]-9H-purin-8-yl}-amine or other derivatives useful for treating an interleukin-12 overproduction-related disorder such as rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis or diabetes | SYNTA PHARMACEUTICALS CORP. | 2004-10-07 | — | — | US | disclosed |
| WO-2004035740-A2 | AROMATIC BICYCLIC HETEROCYLES TO MODULATE 1L - 12 PRODUCTION | SYNTA PHARMACEUTICALS CORP. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | BRCA1, VHL, ESR1 | TYK2 2409/4885SYK 3624/4885IRAK4 2390/4885 |
| US-20040198725-A1 | A bi-heterocyclic compound e.g 3-methoxyphenyl)-{6-Morpholin-4-yl-2-[2-(pyridin-2-yloxy)-ethoxy]-9H-purin-8-yl}-amine or other derivatives useful for treating an interleukin-12 overproduction-related disorder such as rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis or diabetes | MSR1, NGFR, NR0B1 | TYK2 634/4885SYK 974/4885IRAK4 328/4885 |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | BRCA1, VHL, ESR1 | TYK2 2409/4885SYK 3624/4885IRAK4 2390/4885 |
| US-20070027151-A1 | Heterocyclic compounds | NRAS, OXER1, HCRTR2 | TYK2 1141/4885SYK 907/4885IRAK4 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.